Global Nasal Polyps Treatment Market

Nasal Polyps Treatment Comprehensive Study by Application (Hospitals, Clinics, Research Center, Other), Treatment (Medications, Surgery), Diagnosis (CT Scan, MRI Scan, Other), Symptoms (Runny Nose, Stuffy or Blocked Nose, Postnasal Drip, Headache, Snoring, Others) Players and Region - Global Market Outlook to 2030

Nasal Polyps Treatment Market by XX Submarkets | Forecast Years 2024-2030  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
About Nasal Polyps Treatment
Nasal polyps are fleshy swelling that develops in the lining of the nose and paranasal sinuses, the air-filled spaces that are linked to the nasal cavity. It varies in size and may be yellowish-brown or pink. It shaped like teardrops. Large nasal polyps or clusters can cause breathing difficulties and may affect the patient’s sense of smell. It may block sinuses and cause problems. It cannot be cured but they can be treated with medications. Corticosteroid nasal sprays and pills are the most frequently used medications for treating nasal polyps. The antibiotics can be prescribed if the patient has a sinus infection caused by bacteria.

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)


The companies are exploring the market by adopting mergers & acquisitions, expansions, investments, new service launches and collaborations as their preferred strategies. The players are exploring new geographies through expansions and acquisitions to avail a competitive advantage through combined synergies. Analyst at AMA Research estimates that United States Players will contribute the maximum growth to Global Nasal Polyps Treatment market throughout the forecasted period. Established and emerging Players should take a closer view at their existing organizations and reinvent traditional business and operating models to adapt to the future.

OptiNose US, Inc. (United States), Regeneron Pharmaceuticals, Inc. (United States), Merck KGaA (Germany), Pfizer, Inc. (United States), Roche Holding AG (Switzerland), Intersect ENT, Inc. (United States), GlaxoSmithKline plc. (United Kingdom), Novartis (United States), Sanofi (France) and Taro Pharmaceutical Industries Ltd. (United States) are some of the key players that are part of study coverage.

Segmentation Overview
AMA Research has segmented the market of Global Nasal Polyps Treatment market by , Application (Hospitals, Clinics, Research Center and Other) and Region.



On the basis of geography, the market of Nasal Polyps Treatment has been segmented into South America (Brazil, Argentina, Rest of South America), Asia Pacific (China, Japan, India, South Korea, Taiwan, Australia, Rest of Asia-Pacific), Europe (Germany, France, Italy, United Kingdom, Netherlands, Rest of Europe), MEA (Middle East, Africa), North America (United States, Canada, Mexico). If we see Market by Treatment, the sub-segment i.e. Medications will boost the Nasal Polyps Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Diagnosis, the sub-segment i.e. CT Scan will boost the Nasal Polyps Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth. If we see Market by Symptoms, the sub-segment i.e. Runny Nose will boost the Nasal Polyps Treatment market. Additionally, the rising demand from SMEs and various industry verticals gives enough cushion to market growth.

Influencing Trend:
Technological advancements in the treatment

Market Growth Drivers:
Increase in the prevalence of ENT diseases and Rising regulatory approvals for nasal polyp treatment

Challenges:
No complete cure of nasal polyps available

Restraints:
Side effects of the treatment of nasal polyps

Opportunities:
Rising number of hospitals and diagnostic centers worldwide and Development of Healthcare Infrastructure in Emerging Economies

Market Leaders and their expansionary development strategies
In January 2024, GSK and Aiolos Bio, a clinical-stage biopharmaceutical company specializing in the treatment of respiratory and inflammatory conditions, announced that they have entered into an agreement for GSK to acquire Aiolos. hrough the acquisition, GSK will gain access to Aiolos’ AIO-001, a long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody (mAb) that is ready to enter Phase II clinical development. The mAb is being evaluated for the treatment of adult patients with asthma.
On 26th June 2019, The United States Food and Drug Administration approved Dupixent (Dupilumab) to treat adults with nasal polyps accompanied by chronic rhinosinusitis. This is the first treatment approved for inadequately controlled chronic rhinosinusitis with nasal polyps. and In July 2021,,GlaxoSmithKline plc announced that the US Food and Drug Administration (FDA) has approved Nucala (mepolizumab), a monoclonal antibody that targets interleukin-5 (IL-5), as a treatment for patients with chronic rhinosinusitis with nasal polyps (CRSwNP). This new indication for mepolizumab is for the add-on maintenance treatment of CRSwNP in adult patients 18 years of age and older with inadequate response to nasal corticosteroids.


Key Target Audience
Nasal Polyps Treatment Providers, Research Professionals, Emerging Companies, Government Body & Associations and End-user

About Approach
To evaluate and validate the market size various sources including primary and secondary analysis is utilized. AMA Research follows regulatory standards such as NAICS/SIC/ICB/TRCB, to have a better understanding of the market. The market study is conducted on basis of more than 200 companies dealing in the market regional as well as global areas with the purpose to understand the companies positioning regarding the market value, volume, and their market share for regional as well as global.

Further to bring relevance specific to any niche market we set and apply a number of criteria like Geographic Footprints, Regional Segments of Revenue, Operational Centres, etc. The next step is to finalize a team (In-House + Data Agencies) who then starts collecting C & D level executives and profiles, Industry experts, Opinion leaders, etc., and work towards appointment generation.

The primary research is performed by taking the interviews of executives of various companies dealing in the market as well as using the survey reports, research institute, and latest research reports. Meanwhile, the analyst team keeps preparing a set of questionnaires, and after getting the appointee list; the target audience is then tapped and segregated with various mediums and channels that are feasible for making connections that including email communication, telephonic, skype, LinkedIn Group & InMail, Community Forums, Community Forums, open Survey, SurveyMonkey, etc.

Report Objectives / Segmentation Covered

By Application
  • Hospitals
  • Clinics
  • Research Center
  • Other
By Treatment
  • Medications
  • Surgery

By Diagnosis
  • CT Scan
  • MRI Scan
  • Other

By Symptoms
  • Runny Nose
  • Stuffy or Blocked Nose
  • Postnasal Drip
  • Headache
  • Snoring
  • Others

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Increase in the prevalence of ENT diseases
      • 3.2.2. Rising regulatory approvals for nasal polyp treatment
    • 3.3. Market Challenges
      • 3.3.1. No complete cure of nasal polyps available
    • 3.4. Market Trends
      • 3.4.1. Technological advancements in the treatment
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Nasal Polyps Treatment, by Application, Treatment, Diagnosis, Symptoms and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Nasal Polyps Treatment (Value)
      • 5.2.1. Global Nasal Polyps Treatment by: Application (Value)
        • 5.2.1.1. Hospitals
        • 5.2.1.2. Clinics
        • 5.2.1.3. Research Center
        • 5.2.1.4. Other
      • 5.2.2. Global Nasal Polyps Treatment by: Treatment (Value)
        • 5.2.2.1. Medications
        • 5.2.2.2. Surgery
      • 5.2.3. Global Nasal Polyps Treatment by: Diagnosis (Value)
        • 5.2.3.1. CT Scan
        • 5.2.3.2. MRI Scan
        • 5.2.3.3. Other
      • 5.2.4. Global Nasal Polyps Treatment by: Symptoms (Value)
        • 5.2.4.1. Runny Nose
        • 5.2.4.2. Stuffy or Blocked Nose
        • 5.2.4.3. Postnasal Drip
        • 5.2.4.4. Headache
        • 5.2.4.5. Snoring
        • 5.2.4.6. Others
      • 5.2.5. Global Nasal Polyps Treatment Region
        • 5.2.5.1. South America
          • 5.2.5.1.1. Brazil
          • 5.2.5.1.2. Argentina
          • 5.2.5.1.3. Rest of South America
        • 5.2.5.2. Asia Pacific
          • 5.2.5.2.1. China
          • 5.2.5.2.2. Japan
          • 5.2.5.2.3. India
          • 5.2.5.2.4. South Korea
          • 5.2.5.2.5. Taiwan
          • 5.2.5.2.6. Australia
          • 5.2.5.2.7. Rest of Asia-Pacific
        • 5.2.5.3. Europe
          • 5.2.5.3.1. Germany
          • 5.2.5.3.2. France
          • 5.2.5.3.3. Italy
          • 5.2.5.3.4. United Kingdom
          • 5.2.5.3.5. Netherlands
          • 5.2.5.3.6. Rest of Europe
        • 5.2.5.4. MEA
          • 5.2.5.4.1. Middle East
          • 5.2.5.4.2. Africa
        • 5.2.5.5. North America
          • 5.2.5.5.1. United States
          • 5.2.5.5.2. Canada
          • 5.2.5.5.3. Mexico
  • 6. Nasal Polyps Treatment: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. OptiNose US, Inc. (United States)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Regeneron Pharmaceuticals, Inc. (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Merck KGaA (Germany)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Pfizer, Inc. (United States)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Roche Holding AG (Switzerland)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. Intersect ENT, Inc. (United States)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. GlaxoSmithKline plc. (United Kingdom)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Novartis (United States)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Sanofi (France)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Taro Pharmaceutical Industries Ltd. (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Nasal Polyps Treatment Sale, by Application, Treatment, Diagnosis, Symptoms and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Nasal Polyps Treatment (Value)
      • 7.2.1. Global Nasal Polyps Treatment by: Application (Value)
        • 7.2.1.1. Hospitals
        • 7.2.1.2. Clinics
        • 7.2.1.3. Research Center
        • 7.2.1.4. Other
      • 7.2.2. Global Nasal Polyps Treatment by: Treatment (Value)
        • 7.2.2.1. Medications
        • 7.2.2.2. Surgery
      • 7.2.3. Global Nasal Polyps Treatment by: Diagnosis (Value)
        • 7.2.3.1. CT Scan
        • 7.2.3.2. MRI Scan
        • 7.2.3.3. Other
      • 7.2.4. Global Nasal Polyps Treatment by: Symptoms (Value)
        • 7.2.4.1. Runny Nose
        • 7.2.4.2. Stuffy or Blocked Nose
        • 7.2.4.3. Postnasal Drip
        • 7.2.4.4. Headache
        • 7.2.4.5. Snoring
        • 7.2.4.6. Others
      • 7.2.5. Global Nasal Polyps Treatment Region
        • 7.2.5.1. South America
          • 7.2.5.1.1. Brazil
          • 7.2.5.1.2. Argentina
          • 7.2.5.1.3. Rest of South America
        • 7.2.5.2. Asia Pacific
          • 7.2.5.2.1. China
          • 7.2.5.2.2. Japan
          • 7.2.5.2.3. India
          • 7.2.5.2.4. South Korea
          • 7.2.5.2.5. Taiwan
          • 7.2.5.2.6. Australia
          • 7.2.5.2.7. Rest of Asia-Pacific
        • 7.2.5.3. Europe
          • 7.2.5.3.1. Germany
          • 7.2.5.3.2. France
          • 7.2.5.3.3. Italy
          • 7.2.5.3.4. United Kingdom
          • 7.2.5.3.5. Netherlands
          • 7.2.5.3.6. Rest of Europe
        • 7.2.5.4. MEA
          • 7.2.5.4.1. Middle East
          • 7.2.5.4.2. Africa
        • 7.2.5.5. North America
          • 7.2.5.5.1. United States
          • 7.2.5.5.2. Canada
          • 7.2.5.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Nasal Polyps Treatment: by Application(USD Million)
  • Table 2. Nasal Polyps Treatment Hospitals , by Region USD Million (2018-2023)
  • Table 3. Nasal Polyps Treatment Clinics , by Region USD Million (2018-2023)
  • Table 4. Nasal Polyps Treatment Research Center , by Region USD Million (2018-2023)
  • Table 5. Nasal Polyps Treatment Other , by Region USD Million (2018-2023)
  • Table 6. Nasal Polyps Treatment: by Treatment(USD Million)
  • Table 7. Nasal Polyps Treatment Medications , by Region USD Million (2018-2023)
  • Table 8. Nasal Polyps Treatment Surgery , by Region USD Million (2018-2023)
  • Table 9. Nasal Polyps Treatment: by Diagnosis(USD Million)
  • Table 10. Nasal Polyps Treatment CT Scan , by Region USD Million (2018-2023)
  • Table 11. Nasal Polyps Treatment MRI Scan , by Region USD Million (2018-2023)
  • Table 12. Nasal Polyps Treatment Other , by Region USD Million (2018-2023)
  • Table 13. Nasal Polyps Treatment: by Symptoms(USD Million)
  • Table 14. Nasal Polyps Treatment Runny Nose , by Region USD Million (2018-2023)
  • Table 15. Nasal Polyps Treatment Stuffy or Blocked Nose , by Region USD Million (2018-2023)
  • Table 16. Nasal Polyps Treatment Postnasal Drip , by Region USD Million (2018-2023)
  • Table 17. Nasal Polyps Treatment Headache , by Region USD Million (2018-2023)
  • Table 18. Nasal Polyps Treatment Snoring , by Region USD Million (2018-2023)
  • Table 19. Nasal Polyps Treatment Others , by Region USD Million (2018-2023)
  • Table 20. South America Nasal Polyps Treatment, by Country USD Million (2018-2023)
  • Table 21. South America Nasal Polyps Treatment, by Application USD Million (2018-2023)
  • Table 22. South America Nasal Polyps Treatment, by Treatment USD Million (2018-2023)
  • Table 23. South America Nasal Polyps Treatment, by Diagnosis USD Million (2018-2023)
  • Table 24. South America Nasal Polyps Treatment, by Symptoms USD Million (2018-2023)
  • Table 25. Brazil Nasal Polyps Treatment, by Application USD Million (2018-2023)
  • Table 26. Brazil Nasal Polyps Treatment, by Treatment USD Million (2018-2023)
  • Table 27. Brazil Nasal Polyps Treatment, by Diagnosis USD Million (2018-2023)
  • Table 28. Brazil Nasal Polyps Treatment, by Symptoms USD Million (2018-2023)
  • Table 29. Argentina Nasal Polyps Treatment, by Application USD Million (2018-2023)
  • Table 30. Argentina Nasal Polyps Treatment, by Treatment USD Million (2018-2023)
  • Table 31. Argentina Nasal Polyps Treatment, by Diagnosis USD Million (2018-2023)
  • Table 32. Argentina Nasal Polyps Treatment, by Symptoms USD Million (2018-2023)
  • Table 33. Rest of South America Nasal Polyps Treatment, by Application USD Million (2018-2023)
  • Table 34. Rest of South America Nasal Polyps Treatment, by Treatment USD Million (2018-2023)
  • Table 35. Rest of South America Nasal Polyps Treatment, by Diagnosis USD Million (2018-2023)
  • Table 36. Rest of South America Nasal Polyps Treatment, by Symptoms USD Million (2018-2023)
  • Table 37. Asia Pacific Nasal Polyps Treatment, by Country USD Million (2018-2023)
  • Table 38. Asia Pacific Nasal Polyps Treatment, by Application USD Million (2018-2023)
  • Table 39. Asia Pacific Nasal Polyps Treatment, by Treatment USD Million (2018-2023)
  • Table 40. Asia Pacific Nasal Polyps Treatment, by Diagnosis USD Million (2018-2023)
  • Table 41. Asia Pacific Nasal Polyps Treatment, by Symptoms USD Million (2018-2023)
  • Table 42. China Nasal Polyps Treatment, by Application USD Million (2018-2023)
  • Table 43. China Nasal Polyps Treatment, by Treatment USD Million (2018-2023)
  • Table 44. China Nasal Polyps Treatment, by Diagnosis USD Million (2018-2023)
  • Table 45. China Nasal Polyps Treatment, by Symptoms USD Million (2018-2023)
  • Table 46. Japan Nasal Polyps Treatment, by Application USD Million (2018-2023)
  • Table 47. Japan Nasal Polyps Treatment, by Treatment USD Million (2018-2023)
  • Table 48. Japan Nasal Polyps Treatment, by Diagnosis USD Million (2018-2023)
  • Table 49. Japan Nasal Polyps Treatment, by Symptoms USD Million (2018-2023)
  • Table 50. India Nasal Polyps Treatment, by Application USD Million (2018-2023)
  • Table 51. India Nasal Polyps Treatment, by Treatment USD Million (2018-2023)
  • Table 52. India Nasal Polyps Treatment, by Diagnosis USD Million (2018-2023)
  • Table 53. India Nasal Polyps Treatment, by Symptoms USD Million (2018-2023)
  • Table 54. South Korea Nasal Polyps Treatment, by Application USD Million (2018-2023)
  • Table 55. South Korea Nasal Polyps Treatment, by Treatment USD Million (2018-2023)
  • Table 56. South Korea Nasal Polyps Treatment, by Diagnosis USD Million (2018-2023)
  • Table 57. South Korea Nasal Polyps Treatment, by Symptoms USD Million (2018-2023)
  • Table 58. Taiwan Nasal Polyps Treatment, by Application USD Million (2018-2023)
  • Table 59. Taiwan Nasal Polyps Treatment, by Treatment USD Million (2018-2023)
  • Table 60. Taiwan Nasal Polyps Treatment, by Diagnosis USD Million (2018-2023)
  • Table 61. Taiwan Nasal Polyps Treatment, by Symptoms USD Million (2018-2023)
  • Table 62. Australia Nasal Polyps Treatment, by Application USD Million (2018-2023)
  • Table 63. Australia Nasal Polyps Treatment, by Treatment USD Million (2018-2023)
  • Table 64. Australia Nasal Polyps Treatment, by Diagnosis USD Million (2018-2023)
  • Table 65. Australia Nasal Polyps Treatment, by Symptoms USD Million (2018-2023)
  • Table 66. Rest of Asia-Pacific Nasal Polyps Treatment, by Application USD Million (2018-2023)
  • Table 67. Rest of Asia-Pacific Nasal Polyps Treatment, by Treatment USD Million (2018-2023)
  • Table 68. Rest of Asia-Pacific Nasal Polyps Treatment, by Diagnosis USD Million (2018-2023)
  • Table 69. Rest of Asia-Pacific Nasal Polyps Treatment, by Symptoms USD Million (2018-2023)
  • Table 70. Europe Nasal Polyps Treatment, by Country USD Million (2018-2023)
  • Table 71. Europe Nasal Polyps Treatment, by Application USD Million (2018-2023)
  • Table 72. Europe Nasal Polyps Treatment, by Treatment USD Million (2018-2023)
  • Table 73. Europe Nasal Polyps Treatment, by Diagnosis USD Million (2018-2023)
  • Table 74. Europe Nasal Polyps Treatment, by Symptoms USD Million (2018-2023)
  • Table 75. Germany Nasal Polyps Treatment, by Application USD Million (2018-2023)
  • Table 76. Germany Nasal Polyps Treatment, by Treatment USD Million (2018-2023)
  • Table 77. Germany Nasal Polyps Treatment, by Diagnosis USD Million (2018-2023)
  • Table 78. Germany Nasal Polyps Treatment, by Symptoms USD Million (2018-2023)
  • Table 79. France Nasal Polyps Treatment, by Application USD Million (2018-2023)
  • Table 80. France Nasal Polyps Treatment, by Treatment USD Million (2018-2023)
  • Table 81. France Nasal Polyps Treatment, by Diagnosis USD Million (2018-2023)
  • Table 82. France Nasal Polyps Treatment, by Symptoms USD Million (2018-2023)
  • Table 83. Italy Nasal Polyps Treatment, by Application USD Million (2018-2023)
  • Table 84. Italy Nasal Polyps Treatment, by Treatment USD Million (2018-2023)
  • Table 85. Italy Nasal Polyps Treatment, by Diagnosis USD Million (2018-2023)
  • Table 86. Italy Nasal Polyps Treatment, by Symptoms USD Million (2018-2023)
  • Table 87. United Kingdom Nasal Polyps Treatment, by Application USD Million (2018-2023)
  • Table 88. United Kingdom Nasal Polyps Treatment, by Treatment USD Million (2018-2023)
  • Table 89. United Kingdom Nasal Polyps Treatment, by Diagnosis USD Million (2018-2023)
  • Table 90. United Kingdom Nasal Polyps Treatment, by Symptoms USD Million (2018-2023)
  • Table 91. Netherlands Nasal Polyps Treatment, by Application USD Million (2018-2023)
  • Table 92. Netherlands Nasal Polyps Treatment, by Treatment USD Million (2018-2023)
  • Table 93. Netherlands Nasal Polyps Treatment, by Diagnosis USD Million (2018-2023)
  • Table 94. Netherlands Nasal Polyps Treatment, by Symptoms USD Million (2018-2023)
  • Table 95. Rest of Europe Nasal Polyps Treatment, by Application USD Million (2018-2023)
  • Table 96. Rest of Europe Nasal Polyps Treatment, by Treatment USD Million (2018-2023)
  • Table 97. Rest of Europe Nasal Polyps Treatment, by Diagnosis USD Million (2018-2023)
  • Table 98. Rest of Europe Nasal Polyps Treatment, by Symptoms USD Million (2018-2023)
  • Table 99. MEA Nasal Polyps Treatment, by Country USD Million (2018-2023)
  • Table 100. MEA Nasal Polyps Treatment, by Application USD Million (2018-2023)
  • Table 101. MEA Nasal Polyps Treatment, by Treatment USD Million (2018-2023)
  • Table 102. MEA Nasal Polyps Treatment, by Diagnosis USD Million (2018-2023)
  • Table 103. MEA Nasal Polyps Treatment, by Symptoms USD Million (2018-2023)
  • Table 104. Middle East Nasal Polyps Treatment, by Application USD Million (2018-2023)
  • Table 105. Middle East Nasal Polyps Treatment, by Treatment USD Million (2018-2023)
  • Table 106. Middle East Nasal Polyps Treatment, by Diagnosis USD Million (2018-2023)
  • Table 107. Middle East Nasal Polyps Treatment, by Symptoms USD Million (2018-2023)
  • Table 108. Africa Nasal Polyps Treatment, by Application USD Million (2018-2023)
  • Table 109. Africa Nasal Polyps Treatment, by Treatment USD Million (2018-2023)
  • Table 110. Africa Nasal Polyps Treatment, by Diagnosis USD Million (2018-2023)
  • Table 111. Africa Nasal Polyps Treatment, by Symptoms USD Million (2018-2023)
  • Table 112. North America Nasal Polyps Treatment, by Country USD Million (2018-2023)
  • Table 113. North America Nasal Polyps Treatment, by Application USD Million (2018-2023)
  • Table 114. North America Nasal Polyps Treatment, by Treatment USD Million (2018-2023)
  • Table 115. North America Nasal Polyps Treatment, by Diagnosis USD Million (2018-2023)
  • Table 116. North America Nasal Polyps Treatment, by Symptoms USD Million (2018-2023)
  • Table 117. United States Nasal Polyps Treatment, by Application USD Million (2018-2023)
  • Table 118. United States Nasal Polyps Treatment, by Treatment USD Million (2018-2023)
  • Table 119. United States Nasal Polyps Treatment, by Diagnosis USD Million (2018-2023)
  • Table 120. United States Nasal Polyps Treatment, by Symptoms USD Million (2018-2023)
  • Table 121. Canada Nasal Polyps Treatment, by Application USD Million (2018-2023)
  • Table 122. Canada Nasal Polyps Treatment, by Treatment USD Million (2018-2023)
  • Table 123. Canada Nasal Polyps Treatment, by Diagnosis USD Million (2018-2023)
  • Table 124. Canada Nasal Polyps Treatment, by Symptoms USD Million (2018-2023)
  • Table 125. Mexico Nasal Polyps Treatment, by Application USD Million (2018-2023)
  • Table 126. Mexico Nasal Polyps Treatment, by Treatment USD Million (2018-2023)
  • Table 127. Mexico Nasal Polyps Treatment, by Diagnosis USD Million (2018-2023)
  • Table 128. Mexico Nasal Polyps Treatment, by Symptoms USD Million (2018-2023)
  • Table 129. Company Basic Information, Sales Area and Its Competitors
  • Table 130. Company Basic Information, Sales Area and Its Competitors
  • Table 131. Company Basic Information, Sales Area and Its Competitors
  • Table 132. Company Basic Information, Sales Area and Its Competitors
  • Table 133. Company Basic Information, Sales Area and Its Competitors
  • Table 134. Company Basic Information, Sales Area and Its Competitors
  • Table 135. Company Basic Information, Sales Area and Its Competitors
  • Table 136. Company Basic Information, Sales Area and Its Competitors
  • Table 137. Company Basic Information, Sales Area and Its Competitors
  • Table 138. Company Basic Information, Sales Area and Its Competitors
  • Table 139. Nasal Polyps Treatment: by Application(USD Million)
  • Table 140. Nasal Polyps Treatment Hospitals , by Region USD Million (2025-2030)
  • Table 141. Nasal Polyps Treatment Clinics , by Region USD Million (2025-2030)
  • Table 142. Nasal Polyps Treatment Research Center , by Region USD Million (2025-2030)
  • Table 143. Nasal Polyps Treatment Other , by Region USD Million (2025-2030)
  • Table 144. Nasal Polyps Treatment: by Treatment(USD Million)
  • Table 145. Nasal Polyps Treatment Medications , by Region USD Million (2025-2030)
  • Table 146. Nasal Polyps Treatment Surgery , by Region USD Million (2025-2030)
  • Table 147. Nasal Polyps Treatment: by Diagnosis(USD Million)
  • Table 148. Nasal Polyps Treatment CT Scan , by Region USD Million (2025-2030)
  • Table 149. Nasal Polyps Treatment MRI Scan , by Region USD Million (2025-2030)
  • Table 150. Nasal Polyps Treatment Other , by Region USD Million (2025-2030)
  • Table 151. Nasal Polyps Treatment: by Symptoms(USD Million)
  • Table 152. Nasal Polyps Treatment Runny Nose , by Region USD Million (2025-2030)
  • Table 153. Nasal Polyps Treatment Stuffy or Blocked Nose , by Region USD Million (2025-2030)
  • Table 154. Nasal Polyps Treatment Postnasal Drip , by Region USD Million (2025-2030)
  • Table 155. Nasal Polyps Treatment Headache , by Region USD Million (2025-2030)
  • Table 156. Nasal Polyps Treatment Snoring , by Region USD Million (2025-2030)
  • Table 157. Nasal Polyps Treatment Others , by Region USD Million (2025-2030)
  • Table 158. South America Nasal Polyps Treatment, by Country USD Million (2025-2030)
  • Table 159. South America Nasal Polyps Treatment, by Application USD Million (2025-2030)
  • Table 160. South America Nasal Polyps Treatment, by Treatment USD Million (2025-2030)
  • Table 161. South America Nasal Polyps Treatment, by Diagnosis USD Million (2025-2030)
  • Table 162. South America Nasal Polyps Treatment, by Symptoms USD Million (2025-2030)
  • Table 163. Brazil Nasal Polyps Treatment, by Application USD Million (2025-2030)
  • Table 164. Brazil Nasal Polyps Treatment, by Treatment USD Million (2025-2030)
  • Table 165. Brazil Nasal Polyps Treatment, by Diagnosis USD Million (2025-2030)
  • Table 166. Brazil Nasal Polyps Treatment, by Symptoms USD Million (2025-2030)
  • Table 167. Argentina Nasal Polyps Treatment, by Application USD Million (2025-2030)
  • Table 168. Argentina Nasal Polyps Treatment, by Treatment USD Million (2025-2030)
  • Table 169. Argentina Nasal Polyps Treatment, by Diagnosis USD Million (2025-2030)
  • Table 170. Argentina Nasal Polyps Treatment, by Symptoms USD Million (2025-2030)
  • Table 171. Rest of South America Nasal Polyps Treatment, by Application USD Million (2025-2030)
  • Table 172. Rest of South America Nasal Polyps Treatment, by Treatment USD Million (2025-2030)
  • Table 173. Rest of South America Nasal Polyps Treatment, by Diagnosis USD Million (2025-2030)
  • Table 174. Rest of South America Nasal Polyps Treatment, by Symptoms USD Million (2025-2030)
  • Table 175. Asia Pacific Nasal Polyps Treatment, by Country USD Million (2025-2030)
  • Table 176. Asia Pacific Nasal Polyps Treatment, by Application USD Million (2025-2030)
  • Table 177. Asia Pacific Nasal Polyps Treatment, by Treatment USD Million (2025-2030)
  • Table 178. Asia Pacific Nasal Polyps Treatment, by Diagnosis USD Million (2025-2030)
  • Table 179. Asia Pacific Nasal Polyps Treatment, by Symptoms USD Million (2025-2030)
  • Table 180. China Nasal Polyps Treatment, by Application USD Million (2025-2030)
  • Table 181. China Nasal Polyps Treatment, by Treatment USD Million (2025-2030)
  • Table 182. China Nasal Polyps Treatment, by Diagnosis USD Million (2025-2030)
  • Table 183. China Nasal Polyps Treatment, by Symptoms USD Million (2025-2030)
  • Table 184. Japan Nasal Polyps Treatment, by Application USD Million (2025-2030)
  • Table 185. Japan Nasal Polyps Treatment, by Treatment USD Million (2025-2030)
  • Table 186. Japan Nasal Polyps Treatment, by Diagnosis USD Million (2025-2030)
  • Table 187. Japan Nasal Polyps Treatment, by Symptoms USD Million (2025-2030)
  • Table 188. India Nasal Polyps Treatment, by Application USD Million (2025-2030)
  • Table 189. India Nasal Polyps Treatment, by Treatment USD Million (2025-2030)
  • Table 190. India Nasal Polyps Treatment, by Diagnosis USD Million (2025-2030)
  • Table 191. India Nasal Polyps Treatment, by Symptoms USD Million (2025-2030)
  • Table 192. South Korea Nasal Polyps Treatment, by Application USD Million (2025-2030)
  • Table 193. South Korea Nasal Polyps Treatment, by Treatment USD Million (2025-2030)
  • Table 194. South Korea Nasal Polyps Treatment, by Diagnosis USD Million (2025-2030)
  • Table 195. South Korea Nasal Polyps Treatment, by Symptoms USD Million (2025-2030)
  • Table 196. Taiwan Nasal Polyps Treatment, by Application USD Million (2025-2030)
  • Table 197. Taiwan Nasal Polyps Treatment, by Treatment USD Million (2025-2030)
  • Table 198. Taiwan Nasal Polyps Treatment, by Diagnosis USD Million (2025-2030)
  • Table 199. Taiwan Nasal Polyps Treatment, by Symptoms USD Million (2025-2030)
  • Table 200. Australia Nasal Polyps Treatment, by Application USD Million (2025-2030)
  • Table 201. Australia Nasal Polyps Treatment, by Treatment USD Million (2025-2030)
  • Table 202. Australia Nasal Polyps Treatment, by Diagnosis USD Million (2025-2030)
  • Table 203. Australia Nasal Polyps Treatment, by Symptoms USD Million (2025-2030)
  • Table 204. Rest of Asia-Pacific Nasal Polyps Treatment, by Application USD Million (2025-2030)
  • Table 205. Rest of Asia-Pacific Nasal Polyps Treatment, by Treatment USD Million (2025-2030)
  • Table 206. Rest of Asia-Pacific Nasal Polyps Treatment, by Diagnosis USD Million (2025-2030)
  • Table 207. Rest of Asia-Pacific Nasal Polyps Treatment, by Symptoms USD Million (2025-2030)
  • Table 208. Europe Nasal Polyps Treatment, by Country USD Million (2025-2030)
  • Table 209. Europe Nasal Polyps Treatment, by Application USD Million (2025-2030)
  • Table 210. Europe Nasal Polyps Treatment, by Treatment USD Million (2025-2030)
  • Table 211. Europe Nasal Polyps Treatment, by Diagnosis USD Million (2025-2030)
  • Table 212. Europe Nasal Polyps Treatment, by Symptoms USD Million (2025-2030)
  • Table 213. Germany Nasal Polyps Treatment, by Application USD Million (2025-2030)
  • Table 214. Germany Nasal Polyps Treatment, by Treatment USD Million (2025-2030)
  • Table 215. Germany Nasal Polyps Treatment, by Diagnosis USD Million (2025-2030)
  • Table 216. Germany Nasal Polyps Treatment, by Symptoms USD Million (2025-2030)
  • Table 217. France Nasal Polyps Treatment, by Application USD Million (2025-2030)
  • Table 218. France Nasal Polyps Treatment, by Treatment USD Million (2025-2030)
  • Table 219. France Nasal Polyps Treatment, by Diagnosis USD Million (2025-2030)
  • Table 220. France Nasal Polyps Treatment, by Symptoms USD Million (2025-2030)
  • Table 221. Italy Nasal Polyps Treatment, by Application USD Million (2025-2030)
  • Table 222. Italy Nasal Polyps Treatment, by Treatment USD Million (2025-2030)
  • Table 223. Italy Nasal Polyps Treatment, by Diagnosis USD Million (2025-2030)
  • Table 224. Italy Nasal Polyps Treatment, by Symptoms USD Million (2025-2030)
  • Table 225. United Kingdom Nasal Polyps Treatment, by Application USD Million (2025-2030)
  • Table 226. United Kingdom Nasal Polyps Treatment, by Treatment USD Million (2025-2030)
  • Table 227. United Kingdom Nasal Polyps Treatment, by Diagnosis USD Million (2025-2030)
  • Table 228. United Kingdom Nasal Polyps Treatment, by Symptoms USD Million (2025-2030)
  • Table 229. Netherlands Nasal Polyps Treatment, by Application USD Million (2025-2030)
  • Table 230. Netherlands Nasal Polyps Treatment, by Treatment USD Million (2025-2030)
  • Table 231. Netherlands Nasal Polyps Treatment, by Diagnosis USD Million (2025-2030)
  • Table 232. Netherlands Nasal Polyps Treatment, by Symptoms USD Million (2025-2030)
  • Table 233. Rest of Europe Nasal Polyps Treatment, by Application USD Million (2025-2030)
  • Table 234. Rest of Europe Nasal Polyps Treatment, by Treatment USD Million (2025-2030)
  • Table 235. Rest of Europe Nasal Polyps Treatment, by Diagnosis USD Million (2025-2030)
  • Table 236. Rest of Europe Nasal Polyps Treatment, by Symptoms USD Million (2025-2030)
  • Table 237. MEA Nasal Polyps Treatment, by Country USD Million (2025-2030)
  • Table 238. MEA Nasal Polyps Treatment, by Application USD Million (2025-2030)
  • Table 239. MEA Nasal Polyps Treatment, by Treatment USD Million (2025-2030)
  • Table 240. MEA Nasal Polyps Treatment, by Diagnosis USD Million (2025-2030)
  • Table 241. MEA Nasal Polyps Treatment, by Symptoms USD Million (2025-2030)
  • Table 242. Middle East Nasal Polyps Treatment, by Application USD Million (2025-2030)
  • Table 243. Middle East Nasal Polyps Treatment, by Treatment USD Million (2025-2030)
  • Table 244. Middle East Nasal Polyps Treatment, by Diagnosis USD Million (2025-2030)
  • Table 245. Middle East Nasal Polyps Treatment, by Symptoms USD Million (2025-2030)
  • Table 246. Africa Nasal Polyps Treatment, by Application USD Million (2025-2030)
  • Table 247. Africa Nasal Polyps Treatment, by Treatment USD Million (2025-2030)
  • Table 248. Africa Nasal Polyps Treatment, by Diagnosis USD Million (2025-2030)
  • Table 249. Africa Nasal Polyps Treatment, by Symptoms USD Million (2025-2030)
  • Table 250. North America Nasal Polyps Treatment, by Country USD Million (2025-2030)
  • Table 251. North America Nasal Polyps Treatment, by Application USD Million (2025-2030)
  • Table 252. North America Nasal Polyps Treatment, by Treatment USD Million (2025-2030)
  • Table 253. North America Nasal Polyps Treatment, by Diagnosis USD Million (2025-2030)
  • Table 254. North America Nasal Polyps Treatment, by Symptoms USD Million (2025-2030)
  • Table 255. United States Nasal Polyps Treatment, by Application USD Million (2025-2030)
  • Table 256. United States Nasal Polyps Treatment, by Treatment USD Million (2025-2030)
  • Table 257. United States Nasal Polyps Treatment, by Diagnosis USD Million (2025-2030)
  • Table 258. United States Nasal Polyps Treatment, by Symptoms USD Million (2025-2030)
  • Table 259. Canada Nasal Polyps Treatment, by Application USD Million (2025-2030)
  • Table 260. Canada Nasal Polyps Treatment, by Treatment USD Million (2025-2030)
  • Table 261. Canada Nasal Polyps Treatment, by Diagnosis USD Million (2025-2030)
  • Table 262. Canada Nasal Polyps Treatment, by Symptoms USD Million (2025-2030)
  • Table 263. Mexico Nasal Polyps Treatment, by Application USD Million (2025-2030)
  • Table 264. Mexico Nasal Polyps Treatment, by Treatment USD Million (2025-2030)
  • Table 265. Mexico Nasal Polyps Treatment, by Diagnosis USD Million (2025-2030)
  • Table 266. Mexico Nasal Polyps Treatment, by Symptoms USD Million (2025-2030)
  • Table 267. Research Programs/Design for This Report
  • Table 268. Key Data Information from Secondary Sources
  • Table 269. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Nasal Polyps Treatment: by Application USD Million (2018-2023)
  • Figure 5. Global Nasal Polyps Treatment: by Treatment USD Million (2018-2023)
  • Figure 6. Global Nasal Polyps Treatment: by Diagnosis USD Million (2018-2023)
  • Figure 7. Global Nasal Polyps Treatment: by Symptoms USD Million (2018-2023)
  • Figure 8. South America Nasal Polyps Treatment Share (%), by Country
  • Figure 9. Asia Pacific Nasal Polyps Treatment Share (%), by Country
  • Figure 10. Europe Nasal Polyps Treatment Share (%), by Country
  • Figure 11. MEA Nasal Polyps Treatment Share (%), by Country
  • Figure 12. North America Nasal Polyps Treatment Share (%), by Country
  • Figure 13. Global Nasal Polyps Treatment share by Players 2023 (%)
  • Figure 14. Global Nasal Polyps Treatment share by Players (Top 3) 2023(%)
  • Figure 15. Global Nasal Polyps Treatment share by Players (Top 5) 2023(%)
  • Figure 16. BCG Matrix for key Companies
  • Figure 17. OptiNose US, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 18. OptiNose US, Inc. (United States) Revenue: by Geography 2023
  • Figure 19. Regeneron Pharmaceuticals, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 20. Regeneron Pharmaceuticals, Inc. (United States) Revenue: by Geography 2023
  • Figure 21. Merck KGaA (Germany) Revenue, Net Income and Gross profit
  • Figure 22. Merck KGaA (Germany) Revenue: by Geography 2023
  • Figure 23. Pfizer, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 24. Pfizer, Inc. (United States) Revenue: by Geography 2023
  • Figure 25. Roche Holding AG (Switzerland) Revenue, Net Income and Gross profit
  • Figure 26. Roche Holding AG (Switzerland) Revenue: by Geography 2023
  • Figure 27. Intersect ENT, Inc. (United States) Revenue, Net Income and Gross profit
  • Figure 28. Intersect ENT, Inc. (United States) Revenue: by Geography 2023
  • Figure 29. GlaxoSmithKline plc. (United Kingdom) Revenue, Net Income and Gross profit
  • Figure 30. GlaxoSmithKline plc. (United Kingdom) Revenue: by Geography 2023
  • Figure 31. Novartis (United States) Revenue, Net Income and Gross profit
  • Figure 32. Novartis (United States) Revenue: by Geography 2023
  • Figure 33. Sanofi (France) Revenue, Net Income and Gross profit
  • Figure 34. Sanofi (France) Revenue: by Geography 2023
  • Figure 35. Taro Pharmaceutical Industries Ltd. (United States) Revenue, Net Income and Gross profit
  • Figure 36. Taro Pharmaceutical Industries Ltd. (United States) Revenue: by Geography 2023
  • Figure 37. Global Nasal Polyps Treatment: by Application USD Million (2025-2030)
  • Figure 38. Global Nasal Polyps Treatment: by Treatment USD Million (2025-2030)
  • Figure 39. Global Nasal Polyps Treatment: by Diagnosis USD Million (2025-2030)
  • Figure 40. Global Nasal Polyps Treatment: by Symptoms USD Million (2025-2030)
  • Figure 41. South America Nasal Polyps Treatment Share (%), by Country
  • Figure 42. Asia Pacific Nasal Polyps Treatment Share (%), by Country
  • Figure 43. Europe Nasal Polyps Treatment Share (%), by Country
  • Figure 44. MEA Nasal Polyps Treatment Share (%), by Country
  • Figure 45. North America Nasal Polyps Treatment Share (%), by Country
List of companies from research coverage that are profiled in the study
  • OptiNose US, Inc. (United States)
  • Regeneron Pharmaceuticals, Inc. (United States)
  • Merck KGaA (Germany)
  • Pfizer, Inc. (United States)
  • Roche Holding AG (Switzerland)
  • Intersect ENT, Inc. (United States)
  • GlaxoSmithKline plc. (United Kingdom)
  • Novartis (United States)
  • Sanofi (France)
  • Taro Pharmaceutical Industries Ltd. (United States)
Select User Access Type

Key Highlights of Report


Apr 2024 265 Pages 85 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Nasal Polyps Treatment Market Quantitative research analysis
Global Nasal Polyps Treatment Market Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

The standard version of the report profiles players such as OptiNose US, Inc. (United States), Regeneron Pharmaceuticals, Inc. (United States), Merck KGaA (Germany), Pfizer, Inc. (United States), Roche Holding AG (Switzerland), Intersect ENT, Inc. (United States), GlaxoSmithKline plc. (United Kingdom), Novartis (United States), Sanofi (France) and Taro Pharmaceutical Industries Ltd. (United States) etc.
The Study can be customized subject to feasibility and data availability. Please connect with our sales representative for further information.
"Technological advancements in the treatment" is seen as one of major influencing trends for Nasal Polyps Treatment Market during projected period 2023-2030.
The Nasal Polyps Treatment market study includes a random mix of players, including both market leaders and some top growing emerging players. Connect with our sales executive to get a complete company list in our research coverage.

Know More About Global Nasal Polyps Treatment Market Report?

Have a Query? Click Here

Other Related Reports

Vitiligo Treatment Comprehensive Study by Type (Topical Treatment, Light Therapy, Surgical Procedures, Others), Application (Hospitals, Aesthetic Clinics, Others), Drugs (ARN-4079, ATI-50001, AX-1602...
$ 3650
Bulimia Nervosa Treatment Comprehensive Study by Therapy (Support group, Cognitive behavioral therapy, Cognitive therapy, Diaelectical behavior therapy, Counseling psychology, Family therapy, Others)...
$ 3750
Scoliosis Management Comprehensive Study by Type (Juvenile Idiopathic Scoliosis, Infantile Idiopathic Scoliosis, Adolescent Idiopathic Scoliosis), Application (Pediatric, Adult), Treatment (Painkilli...
$ 3450
Sleeping Bruxism Treatment Comprehensive Study by Type (Dental Approaches, Medication), Application (Pediatric, Adult), Diagnosis (Clinical Examination, Electromyographic Methods, Polysomnography, X-...
$ 3950
Amino Acid Metabolism Disorders Treatment Comprehensive Study by Application (Argininosuccinic acidemia, Citrullinemia, Homocystinuria, Maple syrup urine disease, Phenylketonuria, Tyrosinemia type I)...
$ 3650
Addictions Therapeutics Comprehensive Study by Type (Therapy, Medications and Treatment (Nalaxone, Naltrexone, Bupropion, Disulfiram, Nicotine replacement products, Methadone, Varenicline)), Applicat...
$ 3450